Ophthalmic Clinical Trials Market Size Projected to Reach $3.18 billion by 2034 | 6.61%

Straits Research released its highly anticipated report, “Global Ophthalmic Clinical Trials Market Size & Outlook, 2026-2034”. The global ophthalmic clinical trials market size reached USD 1.79 billion in 2025 and is anticipated to grow to USD 3.18 billion by 2034, expanding at a CAGR of 6.61% over the forecast period from 2026 to 2034.

Market Dynamics

The growth of the global ophthalmic clinical trials market is strongly driven by the increasing prevalence of ophthalmic disorders such as age-related macular degeneration, glaucoma, diabetic retinopathy, and dry eye disease, coupled with the rising aging population worldwide. According to the World Health Organization (WHO), over 2.2 billion people globally suffer from some form of vision impairment, underscoring the growing need for effective therapeutic interventions and robust clinical research. Furthermore, advancements in ophthalmic imaging technologies, digital trial monitoring, and biomarker-based patient stratification are accelerating the efficiency and accuracy of ophthalmic trials, thereby fostering market expansion.

However, the market faces restraints such as the high operational costs and complexities associated with ophthalmic trials, mainly in recruiting and retaining patients due to the need for long-term follow-ups and precise visual function measurements. On the other hand, the growing focus on gene therapy, cell-based therapeutics, and regenerative medicine for ocular diseases presents a major opportunity for the ophthalmic clinical trials market. The rapid development of novel modalities targeting rare and inherited retinal disorders supported by favorable regulatory designations like Orphan Drug and Fast Track approvals is expected to expand the pipeline of ophthalmic candidates.

Market Highlights

• Phase: The clinical phase segment dominated the market with a revenue share of 71.69% in 2025.
• Therapeutic Modality: The devices segment is estimated to grow at the fastest CAGR of 7.27% during the forecast period.
• Indication: The cataract & refractive segment dominated the market in 2025 with a revenue share of 23.85%.
• Sponsor Type: The others segment is expected to register the fastest CAGR of 7.03%, owing to growing clinical trials conducted by CROs and academic institutes.
• Regional Insights: North America dominated the market, accounting for more than 40% of market share in 2025, owing to the rise in the prevalence of eye diseases.

Market Segments

1. By Phase (2026-2034)
   1. Discovery Phase
   2. Preclinical Phase
   3. Clinical Phase
      1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
2. By Therapeutic Modality (2026-2034)
   1. Drugs
      1. Small molecules
      2. Biologics
      3. Cell & Gene Therapies
   2. Devices
      1. Surgical & Diagnostics Devices
      2. Vision Care Devices
   3. Others
3. By Indication (2026-2034)
   1. Glaucoma
   2. Macular Degeneration
   3. Dry Eye Disease
   4. Cataract & refractive
   5. Uveitis
   6. Retinopathy
   7. Others
4. By Sponsor Type (2026-2034)
   1. Pharmaceutical & Biopharma Companies
   2. Medical Device Companies
   3. Others